US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redwood Pharma files for bankruptcy

The Board of Directors of Redwood Pharma Aktiebolag (publ) ("Redwood Pharma" or the "Company") has today, on July 28, 2024, decided to file for bankruptcy of the Company. The bankruptcy application will be submitted to the Stockholm District Court as soon as possible.The reason for the bankruptcy filing is that, despite intensive work in 2024, Redwood Pharma has not found a sound and workable solution for its strained financial situation in the short and medium terms. Unfortunately, under the current circumstances, this work has been fruitless, despite the fact that submission of the

Redwood Pharma provides a new update regarding divestment of company assets

Stockholm, June 26, 2024. Redwood Pharma today provides an update on the process for divesting the company's assets. After contacts and discussions with a number of potential buyers in the field of ophthalmology, Redwood Pharma has not received any significant offers with commercially attractive terms. The board of directors is evaluating the situation and will provide more information shortly.Redwood Pharma, a company developing next-generation treatments for dry eye, announced on May 23 that due to financial difficulties, it intends to sell the company's assets in an accelerated auction

Redwood Pharma provides an update on the process for divesting the company's assets

Stockholm, 12 June 2024. Redwood Pharma AB (publ) today provides an update on the process for divesting the company's assets. A number of ophthalmology companies in the USA, Europe and Asia have been invited to participate in an auction process which is expected to be completed during the month of July.Redwood Pharma, a company developing next-generation dry eye treatments, announced on May 23 that due to financial difficulties, it intends to sell off the company's assets in an accelerated auction process, where potential buyers have the opportunity to acquire all or part of the company.

Redwood Pharma provides an update on the company's future

Stockholm, 23 May 2024. Redwood Pharma AB (publ) announces today that the company is evaluating potential solutions to address its strained financial situation. This is in light of the fact that the minimum level was not reached in the new issue that was announced on March 21, 2024, which resulted in the company not having sufficient funds to pay its outstanding debts. The board has begun negotiations with the company's creditors and at the same time initiated a process with the aim of quickly divesting all assets. Any surplus from the sale will be transferred to the shareholders and the

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Redwood Pharma AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Redwood Pharma has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Redwood Pharma to participate in the NLS Days partner conference in Copenhagen

Stockholm, November 22, 2023. Redwood Pharma AB (publ) announces today that the company will participate in Nordic Life Science Days, the Nordics' largest investor and partnering meeting, at the end of November.Redwood Pharma's CEO Martin Vidaeus will participate in the Nordic Life Science Days, NLS Days, organized at the Bella Center in Copenhagen, Denmark, between November 29-30. NLS Days is the Nordic region's leading partner event that brings together investors and companies in the life science industry from several different countries. "Our focus is now on spreading knowledge about

Redwood Pharma to participate in the BIO-Europe partnering conference in Munich

Stockholm, 19 October 2023. Redwood Pharma AB (publ) announces today that the company will participate in BIO-Europe, the life science industry's largest investor and partnering meeting, in November 2023.Redwood Pharma CEO Martin Vidaeus will attend BIO-Europe that will be held in Munich, Germany, between November 6-8. BIO-Europe is Europe's leading partnering event with over 5,500 participants representing 60 countries and over 2,200 companies. The conference creates a unique opportunity for Redwood Pharma to engage in discussions with potential partners. "After the summer, we received

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

Stockholm, 31 May 2023. Redwood Pharma AB (publ) announces positive results from the company's clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye. The results show that RP501 is safe and well-tolerated and that the product produces statistically significant positive results on several subjective efficacy measures, such as burning sensation, stinging and itching.In the study, the safety, tolerability and effect of the treatment were evaluated in people who suffer from dry eye and in contact lens wearers who experience discomfort

Redwood Pharma takes important steps towards the commercial production of its dry eye product

Stockholm, 24 January 2023. Redwood Pharma AB (publ) announces that the company has completed further preparations for the scale-up of production of the company's medical technology product RP501, which is being developed as a treatment for dry eye. As part of the preparations, Redwood Pharma has invested in equipment at the company's manufacturing partner.During 2022, Redwood Pharma has worked to optimize the process and produce a technical production batch of RP501. Once the new equipment has been installed at the contract manufacturer, the company can proceed with adapting the production

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

Stockholm, Sweden, December 15, 2022. Redwood Pharma AB (publ) has entered a partnership with Nextec medical GmbH to act as the Legal Manufacturer for Redwood Pharma´s medical device RP501. The partnership is an important step to ensure a time and resource efficient pathway to obtain CE-mark and facilitate the market introduction of RP501 for the treatment of dry eye disease.Redwood Pharma’s medical device RP501 is being developed as an effective over-the-counter tear substitute for temporary relief of dry eye disease, a medical condition affecting more than 300 million people around the

Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022

Get an update of the development activities surrounding Redwood Pharma’s two products for the treatment of dry eye disease, its near-term plans for seeking RP501 regulatory approval, scaling up of production, commercialization and launch. More information about the coming rights issue in November is also provided by CEO Martin Vidaeus. To view the presentation and a question and answer session, please see the following link: https://youtu.be/oO_Ytq3idwQ

Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45

Redwood Pharma will participate in the Aktieportföljen Live in Stockholm. CEO Martin Vidaeus will update the market about its products in development including the medical device RP501 which is nearing market clearance/approval. The presentation including a question and answers period will be live-streamed through the Aktieportföljen Live website: https://aktieporfoljen.se The presentation will be held in English. See you on October 11 at 14:45!

BioStock Intestor Meeting: Interview with Redwood Pharma

Stockholmbased Redwood Pharma participated in the BioStock Investor Meeting in September where CEO Martin Vidaeus presented the company’s work. Afterwards, BioStock had the chance to interview Vidaeus who told us more about Redwood Pharma’s projects RP501 and RP101, aimed at the treatment of dry eyes.See the full interview at biostock.se:https://www.biostock.se/en/2022/09/biostock-intestor-meeting-interview-with-redwood-pharma/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Redwood Pharma to present at BioStock Investor Meeting in Stockholm on 14th of Sep. 2022

Redwood Pharma will participate in the BioStock Investor Meeting in Stockholm. CEO Martin Vidaeus will update the market about i.e. developments regarding its products in development including the medical device RP501 which is nearing market clearance/approval.   To join the presentation in person, please register at the following link:  https://www.biostock.se/biostockinvestormeeting/   The number of slots are limited and pre-registration is required – register now to secure your spot!    The presentation inlcuding a question and answers period will be live-streamed

The first patient has started Redwood Pharma’s RP501 treatment for dry eye

(Stockholm, Sweden, May 5, 2022) Redwood Pharma AB (publ) today announces that the first patient has been included in the company’s clinical trial of RP501 and has also started treatment. The RP501 medical device with its innovative thermogelling properties is expected to constitute an effective and unique addition to first-line treatment for patients suffering from dry eye disease. Redwood Pharma’s clinical trial is a single-center study that will be conducted at the Medical University of Vienna, Austria, under the guidance of Principal Investigator Prof. Gerhard Garhöfer. 60 patients

Redwood Pharma to present at the BioStock Life Science Summit in Lund and Stockholm on 8-9 June 2022

Redwood Pharma will participate in the BioStock Life Science Summit in Lund and in Stockholm. CEO Martin Vidaeus will update the market about, among several topics, the start of the RP501 clinical trial - the company's first-line medical technology therapy for dry eye - and the company's plans for the future.   BioStock Life Science Spring Summit offers an important platform for Nordic innovation companies, which get the chance to pitch their projects to both Swedish and international investors, industry colleagues and potential partners. The presentation will be held in English.

Redwood Pharma to attend ARVO (Denver), the most important global conference in ophthalmology

The Association of Researchers in Vision and Ophthalmology will hold their annual meeting in Denver, Colorado (USA) between May 1-4, 2022. ARVO is the world’s leading conference in ophthalmology where researchers from academia and industry can meet to share the latest developments in science and therapeutic development.   Redwood Pharma looks to share developments regarding its RP501 and RP101 therapies for treatment of dry eye disease with potential clinical and commercial partners.   To schedule a meeting please contact:   Martin Vidaeus, CEO Martin.vidaeus@

Redwood Pharma receives approval from the Austrian drug authority to start RP501 clinical trial

Redwood Pharma has received approval from the Austrian Federal Office for Safety in Health Care (BASG) to initiate the clinical trial of RP501, the company’s new drug candidate for first-line treatment of dry eye disease. Following the approval from the Austrian Ethics Commission earlier this month, this is the second and final approval required for the company to begin clinical work.To support future product claims, Redwood Pharma is conducting a single-center trial led by Prof. Gerhard Garhöfer who states, “We are excited to start this trial at the Medical University of Vienna, Austria.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe